Search

Friedreich ataxia (FRDA), the most common autosomal recessive ataxia, is characterized by degeneration of the large sensory neurons and spinocerebellar tracts, cardiomyopathy and increased incidence in diabetes. FRDA is caused by severely reduced levels of frataxin, a mitochondrial protein of unknown function. Yeast knockout models as well as histological and biochemical data from heart biopsies or autopsies of FRDA patients have shown that frataxin defects cause a specific iron-sulfur protein deficiency and intramitochondrial iron accumulation. We have recently shown that complete absence of frataxin in the mouse leads to early embryonic lethality, demonstrating an important role for frataxin during mouse development. Through a conditional gene-targeting approach, we have generated in parallel a striated muscle frataxin-deficient line and a neuron/cardiac muscle frataxin-deficient line, which together reproduce important progressive pathophysiological and biochemical features of the human disease: cardiac hypertrophy without skeletal muscle involvement, large sensory neuron dysfunction without alteration of the small sensory and motor neurons, and deficient activities of complexes I-III of the respiratory chain and of the aconitases. Our models demonstrate time-dependent intramitochondrial iron accumulation in a frataxin-deficient mammal, which occurs after onset of the pathology and after inactivation of the Fe-S-dependent enzymes. These mutant mice represent the first mammalian models to evaluate treatment strategies for the human disease. [ABSTRACT FROM AUTHOR]

Accurate quantification of mRNA by competitive RT-PCR demands that the quality of the cRNA internal standard be strictly controlled and that at least two criteria should be satisfied. First, genomic DNA should be removed from the total RNA being analyzed; second, template DNA should be removed from the cRNA internal standard following in vitro transcription. We observed that the routine use of RNase-free DNase I is insufficient for removing template DNA from cRNA samples and can degrade cRNA. Furthermore, reducing the template DNA before digestion, selectively extracting template DNA, and gel fractionation are all ineffective at completely eliminating template DNA contamination in cRNA standards. A strategy was developed ("inverted" competitive RT-PCR) to quantify template DNA contamination in cRNA standards. Regardless of treatment method, a small percentage of DNA contamination remained in the products of in vitro transcription. Without correction, the number of mRNA copies calculated from competitive RT-PCR is systematically overestimated. The number of template DNAs contaminating the cRNA samples was remarkably large, though as a percentage of the total cRNA, DNA contamination was small and could be easily corrected.